Study of 177Lu-CTR-FAPI for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread or cannot be removed, and standard treatments have not worked or are not available.
- You are 18 or older.
- You are in good physical condition (ECOG score 0 or 1).
- A special PET scan shows your tumor has the FAP protein.
- You have at least one tumor that can be measured on scans.
- Your blood, liver, and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
This trial tests a special radioactive medicine (177Lu-CTR-FAPI) for people with advanced digestive cancers that have high FAP expression. The medicine targets a protein on cancer cells to deliver radiation directly to tumors, potentially slowing their growth.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial is testing an investigational drug called 177Lu-FAP-VG1 for people with advanced solid tumors that have stopped responding to standard therapy. The drug is a type of radiation therapy that targets a protein called FAP, which is found on many cancer cells, to try to shrink the tumor and slow the cancer's growth.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.